A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers-Reference-Cited by-同舟云学术

A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers

Published:2021-02-14 Issue:4 Volume:17 Page:503-508
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Wu Min¹,Li Xiaojiao¹,Sun Jixuan¹,Chen Hong¹,Ding Yanhua¹

Affiliation:

1. Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China

Funder

National Major Scientific and Technological Special Project for Significant New Drug Development during the Thirteenth Five-Year Plan Period of China

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2021.1881480

Reference15 articles.

1. PARP Inhibition in Cancer: An Update on Clinical Development

2. Predicting Enhanced Cell Killing through PARP Inhibition

3. PARP inhibition: PARP1 and beyond

4. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy

5. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers;Cancer Chemotherapy and Pharmacology;2024-05-04

2. Development and validation of a sensitive LC–MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients;Journal of Pharmaceutical and Biomedical Analysis;2024-01

3. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers;Cancer Chemotherapy and Pharmacology;2023-05-11

4. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects;Investigational New Drugs;2023-02-17

5. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers;British Journal of Clinical Pharmacology;2022-02-28